Shanghai Kaibao announced that the “National Essential Drug Catalogue” has been implemented since September 1, 2026. The company and its wholly-owned subsidiaries have included a total of 41 varieties. Of these, 3 new products, including heat-clearing and detoxifying oral liquid, were added, and 4 were transferred out, including pediatric compound sulfamethoxazole tablets. The transferred products were not produced and sold, and there was no real impact on performance. The new entry into the catalogue is conducive to product market expansion and sales. There is no significant impact on performance in the short term. Long-term sales scale may increase, and investors are reminded to be aware of risks.

Shanghai Kaibao announced that the “National Essential Drug Catalogue” has been implemented since September 1, 2026. The company and its wholly-owned subsidiaries have included a total of 41 varieties. Of these, 3 new products, including heat-clearing and detoxifying oral liquid, were added, and 4 were transferred out, including pediatric compound sulfamethoxazole tablets. The transferred products were not produced and sold, and there was no real impact on performance. The new entry into the catalogue is conducive to product market expansion and sales. There is no significant impact on performance in the short term. Long-term sales scale may increase, and investors are reminded to be aware of risks.